KLK3 and prostate cancer: Subgroup analysis showed that patients with a 1-PSA of less than 4.0 ng/mL had a significantly increased risk of developing prostate cancer in the increase group compared with the reference group (adjusted HR = 2.94, 95% CI = 1.14–7.58).